Suppr超能文献

根据 ALL-BFM 2000 方案治疗的儿童非高危前体 B 细胞急性淋巴细胞白血病中,存在 P2RY8-CRLF2 重排与预后不良相关。

Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.

机构信息

Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse 3, Kiel, Germany.

出版信息

Blood. 2010 Jul 1;115(26):5393-7. doi: 10.1182/blood-2009-11-256131. Epub 2010 Apr 8.

Abstract

High-level expression of the cytokine receptor-like factor 2 gene, CRLF2, in precursor B-cell acute lymphoblastic leukemia (pB-ALL) was shown to be caused by a translocation involving the IGH@ locus or a deletion juxtaposing CRLF2 with the P2RY8 promoter. To assess its possible prognostic value, CRLF2 expression was analyzed in 555 childhood pB-ALL patients treated according to the Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster 2000 (ALL-BFM 2000) protocol. Besides CRLF2 rearrangements, high-level CRLF2 expression was seen in cases with supernumerary copies of the CRLF2 locus. On the basis of the detection of CRLF2 rearrangements, a CRLF2 high-expression group (n = 49) was defined. This group had a 6-year relapse incidence of 31% plus or minus 8% compared with 11% plus or minus 1% in the CRLF2 low-expression group (P = .006). This difference was mainly attributable to an extremely high incidence of relapse (71% +/- 19%) in non-high-risk patients with P2RY8-CRLF2 rearrangement. The assessment of CRLF2 aberrations may therefore serve as new stratification tool in Berlin-Frankfurt-Münster-based protocols by identifying additional high-risk patients who may benefit from an intensified and/or targeted treatment.

摘要

在 B 细胞前体急性淋巴细胞白血病(pB-ALL)中,细胞因子受体样因子 2 基因(CRLF2)的高水平表达是由涉及 IGH@基因座的易位或使 CRLF2 与 P2RY8 启动子并列的缺失引起的。为了评估其可能的预后价值,根据急性淋巴细胞白血病柏林-法兰克福-明斯特 2000 年(ALL-BFM 2000)方案,对 555 例儿童 pB-ALL 患者的 CRLF2 表达进行了分析。除了 CRLF2 重排外,还在具有 CRLF2 基因座超数拷贝的病例中观察到高水平的 CRLF2 表达。基于 CRLF2 重排的检测,定义了 CRLF2 高表达组(n = 49)。与 CRLF2 低表达组(6 年复发率为 11% +/- 1%)相比,该组的 6 年复发率为 31% +/- 8%(P =.006)。这种差异主要归因于具有 P2RY8-CRLF2 重排的非高危患者的极高复发率(71% +/- 19%)。因此,CRLF2 异常的评估可能通过识别可能受益于强化和/或靶向治疗的其他高危患者,作为基于柏林-法兰克福-明斯特方案的新分层工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验